Skip to main
  1. Stocks
  2. MBX Biosciences Inc
  3. Forecast
MBX

MBX Stock Forecast & Price Target

MBX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 10%

Bulls say

MBX Biosciences is attractive because its PEP platform is already generating clinical signals that support differentiated dosing convenience and pharmacology, with canvuparatide showing mean serum calcium in range through one year, lower urinary calcium, and about a 1.3 peak-to-trough ratio. The weekly PTH opportunity also appears commercially credible, as the company estimates a roughly $1 billion global PTH market, while canvuparatide’s Phase 3 program could remove about 313 injections annually and still leave room alongside Yorvipath given strong retention and open-label rollover. MBX 4291 adds further upside by targeting monthly obesity dosing after four weekly loading doses, with early 7% weight loss data, 12.5% nausea/vomiting/diarrhea in the first MAD cohort, and $418.6 million in cash providing runway into 2029.

Bears say

MBX Biosciences is a clinical-stage biopharmaceutical company with no current commercial product, so its valuation depends almost entirely on unproven pipeline assets and the ability to fund a long development cycle before any sales materialize. Its lead programs still face meaningful clinical and regulatory risk: MBX 4291’s opportunity hinges on sustained weight loss with acceptable GI tolerability, while canvuparatide and earlier-stage programs could require additional trial changes, longer follow-up, more patients, or further manufacturing work, all of which would raise costs and delay approval. Even if approved, the company may struggle with competition, reimbursement pressure, and commercialization execution, and management expects cash flow breakeven only in 2030 or 2031, leaving significant dilution and financing risk if timelines slip.

MBX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

MBX Analyst Forecast & Price Prediction

Get the latest MBX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MBX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MBX Biosciences Inc (MBX) Forecast

Analysts have given MBX a Buy based on their latest research and market trends.

According to 10 analysts, MBX has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $82.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $82.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MBX Biosciences Inc (MBX)


MBX Analyst Forecast & Price Prediction

Get the latest MBX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MBX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MBX stock data and trends